RARE DISEASES A–Z · LETTER P

Pompe Disease

Pompe disease is an inherited lysosomal storage disorder in which glycogen — stored sugar — accumulates inside muscle cells because the enzyme that should break it down (acid alpha-glucosidase) is missing. It presents in two broad forms: a severe infantile disease of heart and muscle, and a slower late-onset muscle disease.

By Dr. Mohamed Ibrahim, MD, PhD — Assistant Professor of Medicine, Transplant Nephrology, University of Maryland School of Medicine · Last reviewed: November 2026

Rare Diseases A–Z is part of the MedicalVideos.com education program. It is produced independently of sponsors, and any future sponsorship will be labelled on the hub.

In short: Pompe disease is a glycogen storage disease of muscle: a missing lysosomal enzyme weakens muscle and, in babies, the heart; in adults the diaphragm is the danger. Enzyme replacement therapy, started early, has transformed it.

The guide

The basics

Glycogen is the body's stored glucose, kept in muscle for energy. Acid alpha-glucosidase works inside lysosomes to break down the glycogen that arrives there; without it, lysosomes swell with glycogen until muscle cells fail. The infantile form is a race against time: babies are profoundly floppy, feed poorly, and develop a massively enlarged heart that fails within the first year if untreated. The late-onset form — childhood through late adulthood — weakens the hip and trunk muscles first (trouble climbing stairs, rising from chairs, waddling gait) and, distinctively, the diaphragm: breathing is worse lying flat, sleep-disordered breathing and morning headaches appear, and respiratory failure can arrive while walking is still fair. The heart is usually spared in late-onset disease.

How it works

Diagnosis is by enzyme activity — measurable on a dried blood spot, making testing fast — confirmed by GAA genetic testing, which also identifies the common late-onset splice variant and informs family testing. Muscle biopsy is rarely needed now. Assessment centres on breathing: lung function measured sitting and lying (a drop when flat exposes diaphragm weakness), overnight sleep studies, and swallowing and nutrition review; infants get urgent heart imaging. Because late-onset Pompe mimics other muscle diseases (limb-girdle dystrophies, myopathies), and because treatment exists, enzyme testing is recommended in undiagnosed proximal weakness with respiratory involvement. A CK blood test is often modestly raised and can be a first clue.

Day to day

Enzyme replacement therapy — intravenous infusions of acid alpha-glucosidase, usually every two weeks — transformed infantile Pompe from uniformly fatal to survivable, with most treated babies' hearts normalising and many walking. Newer-generation enzymes engineered for better muscle uptake are now available and improve on the original in late-onset disease. Treatment works best started early, before muscle is lost. Supportive care is integral: physiotherapy and exercise within tolerance, non-invasive ventilation at night (and later in the day) for diaphragm weakness, cough assistance, swallowing management, and a protein-adequate diet. Some infants develop immune reactions to the enzyme that need immune-tolerance protocols — another reason care sits in expert centres. Gene therapy trials are in progress.

When to get help

Reviews at a metabolic or neuromuscular centre track breathing (including sleep studies), strength, mobility, nutrition, and vaccination status — respiratory infections are a major risk, so flu, pneumococcal, and COVID vaccination should be current. Report increased breathlessness lying flat, morning headaches, daytime sleepiness, choking, or chest infections early. Anaesthetists and surgeons should know the diagnosis. Family testing follows the recessive pattern (siblings have a 1-in-4 risk), and genetic counselling covers newborn screening questions for future babies in the family — where screening exists, a known family history makes early testing of newborns straightforward and genuinely life-changing.

See a doctor promptly if: Breathlessness that is worse lying flat, severe morning headaches, or a chest infection in someone with Pompe disease needs prompt assessment — the diaphragm may be failing.

Common questions

Who was Pompe?

It is named after Joannes Pompe, a Dutch pathologist who described the condition in an infant in 1932. The enzyme defect behind it (acid alpha-glucosidase) was identified decades later, and Pompe disease became the first lysosomal storage disorder of muscle to be characterised.

Does late-onset Pompe affect the heart?

Late-onset Pompe disease does not usually weaken the heart — the cardiac muscle involvement is characteristic of the infantile form. In adults the danger is the breathing muscles, especially the diaphragm, which is why lung function (including lying flat) is monitored so closely.

Is there newborn screening?

Newborn screening for Pompe exists in some regions and is expanding, because infantile Pompe treated within days of birth has dramatically better outcomes. Where screening is not available, a floppy baby with a big heart should trigger urgent enzyme testing.

Does enzyme replacement cure Pompe disease?

Yes — enzyme therapy improves survival and breathing outcomes in infants and stabilises or modestly improves strength and breathing in late-onset disease, but it does not fully reverse established muscle damage. That is why early diagnosis remains the strongest lever, and better enzymes continue to be developed.

More in Letter P

Related

This guide is general information, not medical advice. Rare diseases are individual — diagnosis and treatment depend on your own results, other conditions, and treatment history, and are set by your treating team. Never start, stop, or change a medicine because of something you read here. If you have severe breathlessness, uncontrolled bleeding, confusion, sudden weakness, or thoughts of harming yourself, seek urgent care. Enzyme therapy timing and respiratory support are individual; follow your metabolic centre's plan.